The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Janus kinase (JAK) inhibitors are not associated with an increased risk for gastrointestinal perforation (GIP) among patients with rheumatoid arthritis (RA), according to study results published in ...

Adding perioperative systemic therapy to CRS-HIPEC can improve some outcomes in patients with resectable colorectal peritoneal metastases, data suggest.

While CVS hospitalizations have declined, the illness continues to present among young women, Black individuals, and leads to high costs among Hispanic patients.

Providers favor CPAP and patients prefer tirzepatide for treatment for comorbid obesity and obstructive sleep apnea.

Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine ...

Patients with eosinophilic esophagitis in the US have high health care resource utilization costs, according to a retrospective national claims study.

Sociodemographic disparities, such as low income and lack of health insurance, contribute to reduced CRC screening at age 45 years.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.